The microscopic organisms living in our intestines may influence the severity of Covid-19 and the body’s immune response to it, and could account for lingering symptoms, researchers reported.

Surface Oncology agreed to grant exclusive worldwide licensing rights to GlaxoSmithKline for the development and commercialization of the Cambridge, Mass.-based biotech company’s SRF813, a fully human IgG1 antibody and immunotherapy designed to treat cancer.

Oxford University’s Covid-19 vaccine candidate has a better immune response when a two full-dose regime is used rather than a full-dose followed by a half-dose booster, the university said, citing data from early trials.

Sanofi and GlaxoSmithKline said clinical trials of their Covid-19 vaccine showed an insufficient immune response in older people, delaying its launch to late 2021 and marking a setback in the global fight against the pandemic.

A combination of Canadian drug developer Medicago’s experimental Covid-19 vaccine and a booster from Britain’s GlaxoSmithKline will enter a large study with more than 30,000 volunteers in 2020.

Germany-based CureVac NV published detailed interim Phase I data of the company’s Covid-19 vaccine candidate CVnCoV.

Amgen and AstraZeneca announced that their Phase III NAVIGATOR trial of the potential first-in-class human monoclonal antibody tezepelumab hit the primary endpoint in severe asthma.

Novartis’ IL-1β inhibitor Ilaris (canakinumab) came up short in a Phase III Covid-19 study, the company reported, following an interim analysis of data.

Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.

Leading pharmaceutical companies – including Moderna, Pfizer and AstraZeneca – are racing ahead to develop and distribute a Covid-19 vaccine.